287 related articles for article (PubMed ID: 18989671)
21. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
22. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
25. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
26. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
27. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation.
Brown DL; Masselink AJ; Lalla CD
Ann Pharmacother; 2013; 47(7-8):1039-44. PubMed ID: 23757387
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.
Shord SS; Bressler LR; Radhakrishnan L; Chen N; Villano JL
Ann Pharmacother; 2009 Feb; 43(2):235-41. PubMed ID: 19193580
[TBL] [Abstract][Full Text] [Related]
30. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
31. Estimation of glomerular filtration rate in cancer patients.
Wright JG; Boddy AV; Highley M; Fenwick J; McGill A; Calvert AH
Br J Cancer; 2001 Feb; 84(4):452-9. PubMed ID: 11207037
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin.
Jennings S; de Lemos ML; Levin A; Murray N
J Oncol Pharm Pract; 2010 Jun; 16(2):113-9. PubMed ID: 19578094
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
34. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.
Martin L; Chatelut E; Boneu A; Rostaing L; Roussilhes C; Caselles O; Canal P
Bull Cancer; 1998 Jul; 85(7):631-6. PubMed ID: 9752271
[TBL] [Abstract][Full Text] [Related]
35. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
36. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.
Leader WG; Tsubaki T; Chandler MH
Am J Hosp Pharm; 1994 Sep; 51(17):2125-30. PubMed ID: 7985687
[TBL] [Abstract][Full Text] [Related]
37. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
38. Standardization of p-creatinine assays and use of lean body mass allow improved prediction of calculated glomerular filtration rate in adults: a new equation.
Nyman U; Björk J; Sterner G; Bäck SE; Carlson J; Lindström V; Bakoush O; Grubb A
Scand J Clin Lab Invest; 2006; 66(6):451-68. PubMed ID: 17000553
[TBL] [Abstract][Full Text] [Related]
39. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
